MANAGING MINIMAL RESIDUAL MALIGNANT DISEASE

被引：12

作者：

MATHE, G ^{[1
]}

REIZENSTEIN, P ^{[1
]}

机构：

[1] KAROLINSKA HOSP & INST, DIV HEMATOL, STOCKHOLM, SWEDEN

来源：

关键词：

D O I：

10.1159/000226352

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：137 / 142

页数：6

共 72 条

[51]

ORBACHARBOUYS S, 1984, BEHRING I MITT, V75, P258

[52]

OSBY L, UNPUB PHASE 2 STUDY

[53]

OTA K, 1985, PROGR CANCER IMMUNOT, P86

[54]

PAULI C, 1978, CANCER IMMUNOL IMMUN, V5, P1

[55]

PAVLOVSKY S, 1981, CANCER-AM CANCER SOC, V48, P1500, DOI 10.1002/1097-0142(19811001)48:7<1500::AID-CNCR2820480703>3.0.CO

[56]

2-5

[57]

PINKEL D, 1979, CANCER, V43, P1128, DOI 10.1002/1097-0142(197903)43:3<1128::AID-CNCR2820430352>3.0.CO

[58]

2-Y

[59]

PREHN RT, 1960, CANCER RES, V20, P1614

[60]

REIZENSTEIN P, 1985, ADV IMMUN CANCER THE